Dear readers,
We are glad to announce the launch of our new website, https://uk.webfg.com. There you will continue to have access to the full content of the Sharecast newswire, alongside an improved and expanded suite of market data and research tools for both the UK and the main international markets. As a first step in the transition to the new site, over coming days and weeks the news and data pages on Sharecast.com will redirect you towards the new website which we earnestly hope you will find even more useful than the current service. Should anyone like to comment or provide constructive criticism on the new layout or what features they would like to see added or deleted, do please send us an e-mail to info@digitallook.com. Lastly, of course, we wish to express our heartfelt gratitude for your support and encouragement over the years as we continued to grow and expand the service.
Very best,
Sharecast

Login/Register

AstraZeneca upgraded to 'buy' at Investec despite Mystic setback

Market Buzz

AstraZeneca upgraded to 'buy' at Investec despite Mystic setback

Wed, 09 August 2017
Article viewed 439 times
http://stmedia.digitallook.com/web/img/dl/astrazeneca.jpg
bool(true)
AstraZeneca upgraded to 'buy' at Investec despite Mystic setback
AstraZeneca Quote more

Price: 5,095.00

Chg: -45.00

Chg %: -0.88%

Date: 10:24

(ShareCast News) - Pharmaceutical firm AstraZeneca was upgraded to 'buy' from 'hold' by Investec Securities on Wednesday, despite concerns over Mystic - its ongoing trial for immuno-oncology (IO) drug Imfinizi.
Investec sees improving risk/reward in relation to other clinical datapoints arriving in the near future, excluding Mystic from its valuations in a research note.

AstraZeneca's target price was lowered to 4,900p however, having previously been pegged at 5,000p.

The upgrade comes of the back of a major tanking two weeks ago following the reporting of its first-half results for 2017.

The FTSE 100-listed firm fell 16% on 27 July after disappointing results from the Mystic trial in which its developing lung cancer drug could not meet a primary target of progression-free survival.



The company's total revenue also fell 11% for the first six months of the year, but Investec analysts believe AstraZeneca has enough strength outside Mystic to drive outperformance.

"Despite our belief that MYSTIC still has a reasonable probability of ultimately giving positive data on Overall Survival (OS), due 1H18 or before, we prefer to position our base-case estimates without any MYSTIC contribution," the research note said.

"Expectation for MYSTIC, already in consensus forecasts, was the original reason for our cautious stance in our AZN initiation. With that dissipating, and with other pipeline assets generating robust datasets, we upgrade AZN to Buy with a price target of £49."

The pharmaceutical company's shares were trading 0.81% at 4525p as of 10:40 BST.